QQQ   358.27 (+0.07%)
AAPL   171.21 (+0.30%)
MSFT   315.75 (+0.67%)
META   300.21 (-1.23%)
GOOGL   130.86 (-1.10%)
AMZN   127.12 (+0.90%)
TSLA   250.22 (+1.56%)
NVDA   434.99 (+0.95%)
NIO   9.04 (+1.35%)
BABA   86.75 (+1.41%)
AMD   102.82 (+0.06%)
T   15.03 (+0.13%)
F   12.42 (-1.11%)
MU   68.03 (+4.34%)
CGC   0.78 (-3.69%)
GE   110.55 (-1.59%)
DIS   81.06 (+1.16%)
AMC   7.99 (+2.57%)
PFE   33.18 (+3.40%)
PYPL   58.46 (+0.48%)
NFLX   377.60 (+0.33%)
QQQ   358.27 (+0.07%)
AAPL   171.21 (+0.30%)
MSFT   315.75 (+0.67%)
META   300.21 (-1.23%)
GOOGL   130.86 (-1.10%)
AMZN   127.12 (+0.90%)
TSLA   250.22 (+1.56%)
NVDA   434.99 (+0.95%)
NIO   9.04 (+1.35%)
BABA   86.75 (+1.41%)
AMD   102.82 (+0.06%)
T   15.03 (+0.13%)
F   12.42 (-1.11%)
MU   68.03 (+4.34%)
CGC   0.78 (-3.69%)
GE   110.55 (-1.59%)
DIS   81.06 (+1.16%)
AMC   7.99 (+2.57%)
PFE   33.18 (+3.40%)
PYPL   58.46 (+0.48%)
NFLX   377.60 (+0.33%)
QQQ   358.27 (+0.07%)
AAPL   171.21 (+0.30%)
MSFT   315.75 (+0.67%)
META   300.21 (-1.23%)
GOOGL   130.86 (-1.10%)
AMZN   127.12 (+0.90%)
TSLA   250.22 (+1.56%)
NVDA   434.99 (+0.95%)
NIO   9.04 (+1.35%)
BABA   86.75 (+1.41%)
AMD   102.82 (+0.06%)
T   15.03 (+0.13%)
F   12.42 (-1.11%)
MU   68.03 (+4.34%)
CGC   0.78 (-3.69%)
GE   110.55 (-1.59%)
DIS   81.06 (+1.16%)
AMC   7.99 (+2.57%)
PFE   33.18 (+3.40%)
PYPL   58.46 (+0.48%)
NFLX   377.60 (+0.33%)
QQQ   358.27 (+0.07%)
AAPL   171.21 (+0.30%)
MSFT   315.75 (+0.67%)
META   300.21 (-1.23%)
GOOGL   130.86 (-1.10%)
AMZN   127.12 (+0.90%)
TSLA   250.22 (+1.56%)
NVDA   434.99 (+0.95%)
NIO   9.04 (+1.35%)
BABA   86.75 (+1.41%)
AMD   102.82 (+0.06%)
T   15.03 (+0.13%)
F   12.42 (-1.11%)
MU   68.03 (+4.34%)
CGC   0.78 (-3.69%)
GE   110.55 (-1.59%)
DIS   81.06 (+1.16%)
AMC   7.99 (+2.57%)
PFE   33.18 (+3.40%)
PYPL   58.46 (+0.48%)
NFLX   377.60 (+0.33%)
NASDAQ:KMDA

Kamada (KMDA) Stock Forecast, Price & News

$5.34
+0.09 (+1.71%)
(As of 09/29/2023 ET)
Compare
Today's Range
$5.25
$5.38
50-Day Range
$4.86
$5.83
52-Week Range
$3.72
$5.85
Volume
10,059 shs
Average Volume
32,086 shs
Market Capitalization
$239.34 million
P/E Ratio
66.76
Dividend Yield
N/A
Price Target
$11.00

Kamada MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
106.0% Upside
$11.00 Price Target
Short Interest
Healthy
0.05% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.72mentions of Kamada in the last 14 days
Based on 3 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
250.00%
From $0.06 to $0.21 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.83 out of 5 stars

Medical Sector

40th out of 973 stocks

Pharmaceutical Preparations Industry

11th out of 450 stocks


KMDA stock logo

About Kamada (NASDAQ:KMDA) Stock

Kamada Ltd., together with its subsidiaries, provides plasma-derived protein therapeutics. It operates in two segments, Proprietary Products and Distribution. The company offers WINRHO SDF for immune thrombocytopenic purpura and suppression of rhesus isoimmunization; HEPAGAM B for prevention of hepatitis B recurrence liver transplants and post-exposure prophylaxis; VARIZIG for post exposure prophylaxis of varicella; and GLASSIA for intravenous AATD. It also provides KamRho (D) IM for prophylaxis of hemolytic disease of newborns; KamRho (D) IV for immune thermobocytopunic purpura; and snake bite antiserum to treat snake bites by the vipera palaestinae and echis coloratus. In addition, the company distributes BRAMITOB to manage chronic pulmonary infection; FOSTER to treat asthma; PROVOCHOLINE for the diagnosis of bronchial airway hyperactivity; AEROBIKA, an OPEP device; RUPAFIN for Allergic rhinitis and Urticaria; IVIG for immunodeficiency-related conditions; VARITECT for chicken pox and zoster herpes; ZUTECTRA and HEPATECT CP for hepatitis B; MEGALOTECT CP for cytomegalovirus virus; RUCONEST for angioedema attacks; heparin sodium injection for thrombo-embolic disorders and prophylaxis of deep vein thrombosis and thromboembolic events; ALBUMIN for blood plasma; Factor VIII for hemophilia type A; and Factor IX for hemophilia type B. Further, it offers IXIARO for Japanese encephalitis; VIVOTIF for Salmonella Typhi; PROCYSBI for nephropathic cystinosis; LAMZEDE for alpha-mannosidosis; and ELIGARD for prostate cancer. The company markets its products through strategic partners in the United States, as well as through distributors internationally. It has strategic partnerships with Takeda Pharmaceuticals Company Limited; PARI GmbH; and Kedrion Biopharma. Kamada Ltd. was incorporated in 1990 and is headquartered in Rehovot, Israel.

KMDA Price History

KMDA Stock News Headlines

Better Than Oil Stocks?
The best way to profit from energy is NOT a stock...Rather, it's this little-known alternative investment.
Kamada: Q2 Earnings Snapshot
Kamada earnings preview: what to expect
Better Than Oil Stocks?
The best way to profit from energy is NOT a stock...Rather, it's this little-known alternative investment.
Kamada: Q1 Earnings Insights
Kamada: Q1 Earnings Snapshot
Here's what Wall Street expects from Kamada's earnings
Kamada Q1 2023 Earnings Preview
See More Headlines
Receive KMDA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Kamada and its competitors with MarketBeat's FREE daily newsletter.

KMDA Company Calendar

Last Earnings
8/16/2023
Today
9/29/2023
Next Earnings (Estimated)
11/28/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:KMDA
Employees
380
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$11.00
High Stock Price Forecast
$11.00
Low Stock Price Forecast
$11.00
Forecasted Upside/Downside
+106.0%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
1 Analysts

Profitability

Net Income
$-2,320,000.00
Pretax Margin
2.43%

Debt

Sales & Book Value

Annual Sales
$129.34 million
Cash Flow
$0.03 per share
Book Value
$3.93 per share

Miscellaneous

Free Float
28,640,000
Market Cap
$239.34 million
Optionable
Not Optionable
Beta
0.94
20 Stocks to Sell Now Cover

MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.

Get This Free Report

Key Executives

  • Mr. Amir London (Age 54)
    Chief Exec. Officer
    Comp: $619k
  • Mr. Chaime Orlev (Age 53)
    Chief Financial Officer
    Comp: $396k
  • Mr. Eran Nir (Age 50)
    Chief Operating Officer
    Comp: $371k
  • Mr. Boris Gorelik (Age 42)
    VP of Bus. Devel. & Strategic Programs
    Comp: $337k
  • Mr. David Tsur (Age 73)
    Co-Founder & Deputy Chairman
  • Mr. Nir Livneh B.A. (Age 44)
    L.L.B., VP, Gen. Counsel & Corp. Sec.
  • Ms. Hanni Neheman (Age 53)
    VP of Marketing & Sales
  • Ms. Liron Reshef (Age 52)
    VP of HR
  • Mr. Jon R. Knight
    VP of US Commercial Operations
  • Ms. Shavit Beladev
    VP of Kamada Plasma













KMDA Stock - Frequently Asked Questions

Should I buy or sell Kamada stock right now?

1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Kamada in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" KMDA shares.
View KMDA analyst ratings
or view top-rated stocks.

What is Kamada's stock price forecast for 2023?

1 analysts have issued 12-month price targets for Kamada's shares. Their KMDA share price forecasts range from $11.00 to $11.00. On average, they expect the company's stock price to reach $11.00 in the next twelve months. This suggests a possible upside of 106.0% from the stock's current price.
View analysts price targets for KMDA
or view top-rated stocks among Wall Street analysts.

How have KMDA shares performed in 2023?

Kamada's stock was trading at $4.01 at the beginning of the year. Since then, KMDA shares have increased by 33.2% and is now trading at $5.34.
View the best growth stocks for 2023 here
.

Are investors shorting Kamada?

Kamada saw a decrease in short interest during the month of September. As of September 15th, there was short interest totaling 9,400 shares, a decrease of 29.3% from the August 31st total of 13,300 shares. Based on an average daily volume of 26,500 shares, the days-to-cover ratio is presently 0.4 days. Approximately 0.1% of the company's stock are short sold.
View Kamada's Short Interest
.

When is Kamada's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, November 28th 2023.
View our KMDA earnings forecast
.

How were Kamada's earnings last quarter?

Kamada Ltd. (NASDAQ:KMDA) announced its quarterly earnings data on Wednesday, August, 16th. The biotechnology company reported $0.04 earnings per share for the quarter, topping analysts' consensus estimates of $0.02 by $0.02. The biotechnology company had revenue of $37.44 million for the quarter, compared to the consensus estimate of $34.18 million. Kamada had a net margin of 2.35% and a trailing twelve-month return on equity of 7.42%. During the same period in the previous year, the company posted $0.07 earnings per share.

What guidance has Kamada issued on next quarter's earnings?

Kamada issued an update on its FY 2023 earnings guidance on Wednesday, August, 16th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $138.00 million-$146.00 million, compared to the consensus revenue estimate of $141.36 million.

What other stocks do shareholders of Kamada own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Kamada investors own include CA (CA), BlackRock (BLK), Endologix (ELGX), Chipotle Mexican Grill (CMG), Athabasca Oil (ATH), Allergan (AGN), NIC (EGOV), Micron Technology (MU), Teva Pharmaceutical Industries (TEVA) and Aegean Marine Petroleum Network (ANW).

What is Kamada's stock symbol?

Kamada trades on the NASDAQ under the ticker symbol "KMDA."

How do I buy shares of Kamada?

Shares of KMDA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Kamada's stock price today?

One share of KMDA stock can currently be purchased for approximately $5.34.

How much money does Kamada make?

Kamada (NASDAQ:KMDA) has a market capitalization of $239.34 million and generates $129.34 million in revenue each year. The biotechnology company earns $-2,320,000.00 in net income (profit) each year or $0.08 on an earnings per share basis.

How many employees does Kamada have?

The company employs 380 workers across the globe.

How can I contact Kamada?

Kamada's mailing address is 2 HOLTZMAN ST. SCIENCE PARK, REHOVOT L3, 7670402. The official website for the company is www.kamada.com. The biotechnology company can be reached via phone at (728) 940-6472, via email at ir@kamada.com, or via fax at 972-8940-6473.

This page (NASDAQ:KMDA) was last updated on 9/29/2023 by MarketBeat.com Staff

My Account -